Bethesda system

Lore & Background

The Bethesda system was established at a conference in Bethesda, Maryland, sponsored by the National Institutes of Health. It provides a uniform framework for reporting cervical cytologic diagnoses, including categories such as atypical squamous cells (ASC-US, ASC-H), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), and various glandular cell abnormalities. The system has been revised three times since its introduction. A parallel system, The Bethesda System for Reporting Thyroid Cytopathology, was first introduced at a conference in 2007, with the first atlas published in 2010, dividing results into six categories with specific management recommendations.

Reader's Guide

The Bethesda system is significant because it standardized the reporting of Pap smear results, reducing ambiguity and improving communication between cytopathologists and clinicians. For cervical cytology, it defines specific abnormal results such as LSIL (usually indicating mild dysplasia, often resolving spontaneously) and HSIL (indicating moderate to severe dysplasia, with a risk of progression to invasive cancer if untreated). The system guides clinical management: LSIL may be managed with observation, while HSIL typically prompts immediate colposcopy with biopsy. For thyroid cytology, the Bethesda system categorizes specimens from nondiagnostic to malignant, with corresponding risk of malignancy and recommended actions (e.g., repeat FNAC for nondiagnostic, lobectomy for suspicious). This system has become a global standard, enabling consistent research and patient care.

Did You Know?

• The Bethesda system was introduced in 1988 and revised in 1991, 2001, and 2014.
• The name comes from Bethesda, Maryland, the location of the NIH-sponsored conference that established the system.
• Since 2010, the Bethesda system has been used for thyroid nodule cytopathology, called The Bethesda System for Reporting Thyroid Cytopathology.
• HSIL results correspond to histological classification of CIN 2 or 3, and about 20% would progress to invasive cervical cancer without treatment.

Origins and Institutional Architecture

The Bethesda system for reporting cervical cytology traces its roots to a landmark conference held in Bethesda, Maryland, a location that lent its name to what would become the global standard for Pap smear reporting. Sponsored by the National Institutes of Health, the conference established a unified framework for communicating cervical and vaginal cytologic diagnoses, and the system was formally introduced in 1988. Since then, it has undergone three major revisions—in 1991, 2001, and 2014—reflecting evolving understanding of cervical pathology. The system is published in book editions, with Springer currently serving as the publisher. Its governance and promotion are closely tied to the American Society for Clinical Pathology, which maintains a dedicated website and atlas for the Bethesda system. The institutional backing from NIH and the iterative revision process have given the framework a level of authority and currency that has made it the default language for cytopathology reporting worldwide. When clinicians or pathologists refer to the Bethesda system without further qualification, they are almost always speaking about this cervical cytology standard.

The Cervical Classification Spectrum

The cervical component of the Bethesda system organizes abnormal Pap smear findings into a structured hierarchy that guides clinical decision-making. On the squamous side, results range from atypical squamous cells of undetermined significance (ASC-US) through atypical squamous cells that cannot exclude high-grade lesions (ASC-H), to low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), and finally squamous cell carcinoma. LSIL typically corresponds to mild dysplasia, known as CIN 1, and is most often driven by a human papillomavirus infection. HSIL, by contrast, maps to the more serious CIN 2 or CIN 3 histological categories and carries the potential for progression to invasive cervical cancer. On the glandular side, the system includes atypical glandular cells not otherwise specified (AGC-NOS), atypical glandular cells suspicious for adenocarcinoma in situ or cancer (AGC-neoplastic), adenocarcinoma in situ, and frank adenocarcinoma, which can originate from the endocervix, endometrium, or extrauterine sites. Notably, the term AGC replaced the older designation AGUS specifically to prevent confusion with ASC-US.

Extension to Thyroid Cytopathology

Beginning in 2010, the Bethesda framework expanded beyond cervical screening to encompass the reporting of thyroid nodule fine-needle aspiration cytology, a domain now known as the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC or BSRTC). Like its cervical counterpart, the thyroid system emerged from an NIH-sponsored conference and is likewise published in book editions through Springer. It classifies thyroid cytological specimens into six distinct categories, each carrying a specific recommended management pathway. Category I specimens warrant repeated fine-needle aspiration, while Category II calls for clinical follow-up. Category III prompts a repeat aspiration, Category IV leads to lobectomy, Category V typically requires near-total thyroidectomy or lobectomy, and Category VI—the malignant category—necessitates near-total thyroidectomy. The system's clinical utility is underscored by its risk stratification: a malignant FNAC report carries a 93.7 percent probability of true malignancy, whereas a suspicious report corresponds to an 18.9 percent risk. In everyday medical discourse, references to the Bethesda system default to the cervical version unless the thyroid context is made explicit.

From Diagnosis to Treatment: Clinical Pathways

The Bethesda system's true power lies in how it translates cytologic findings into concrete clinical actions. For LSIL, the standard approach is a watch-and-wait strategy, since CIN 1 usually resolves on its own within two years. However, because roughly twelve to sixteen percent of cases progress to more severe dysplasia, physicians may opt for a colposcopy with biopsy. If progression is confirmed, treatment involves removing or destroying the affected tissue through LEEP, cryosurgery, cone biopsy, or laser ablation. HSIL demands a more urgent response: immediate colposcopy with biopsy to obtain tissue for definitive histological classification, since a Pap smear alone provides only a cytologic picture. Treatment for HSIL—most commonly LEEP, though cryotherapy, cautery, or laser ablation are alternatives—carries an approximately eighty-five percent cure rate. Importantly, these procedures are withheld from pregnant women unless invasive cancer is present, per 2006 ASCCP consensus guidelines. For AGC findings, management involves colposcopy with or without an endometrial biopsy, reflecting the glandular origin of the abnormality.